1. The cancer immunotherapy revolution;Kelly;Science,2018
2. Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings;Castañon;Eur J Cancer,2020
3. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1;Champiat;Clin. Cancer Res. AACR,2017
4. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects;Royston;Stat. Med. Wiley Online Library,2002
5. Why do phase III clinical trials in oncology fail so often?;Amiri-Kordestani;JNCI J. Natl. Cancer Inst. [Internet],2012